


BASIC SCIENCE ABSTRACTS

International Congress of Parkinson's Disease and Movement Disorders®



August 27-31, 2023
Copenhagen
DENMARK



International Parkinson and
Movement Disorder Society

Basic Science

152

Expression profile of circRNA in peripheral blood mononuclear cells of patients with Parkinson's disease and atypical parkinsonian syndromes

153

Exosomal α -synuclein in Multiple system atrophy and parkinson's disease cause distinct synucleinopathies

154

In vivo proteomic investigation of deeply phenotyped parkinsonian syndromes for biomarkers of differential diagnosis

155

Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy

187

A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy

188

Evaluation of a novel Phosphodiesterase 5 inhibitor as a potential therapeutic agent in P301S transgenic mouse model of tauopathy.

189

Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept

237

A vicious cycle of karyopherin abnormalities in synucleinopathies

269

Analysis of the network of genes related to Parkinson's and identification of key proteins

270

Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism

339

Protective effect and mechanism of TREM2 in Parkinson's disease with cognitive impairment

403

Effects of *Eromomastax speciosa* in a Gastric Ulcer in a 6-hydroxydopamine (6-OHDA)-induced Rat Model of Parkinson's Disease.

404

Ramelteon ameliorates abnormal sleep-wake behavior in a zebrafish model of Parkinson's disease by facilitating abnormal lipid metabolism

593

Tramadol Induces Neuroinflammation, Mitochondrial Oxidative Stress, Neurotransmitters Dysbalanced and Produced Parkinson's Disease Like Symptoms in Experimental Wistar Rats

594

Quercetin hinders Glial Activation to Alleviate the Cadmium Induced Dopaminergic Alteration via TNF α mediated CAMKII α /ERK activation

595

Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson's disease

596

The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson's disease

597

Hesperidin ameliorates rotenone-induced Parkinson's disease in mice via improving neuroinflammation and oxidative stress

676

The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.

742

Calcium phenotype in cellular models of VPS13A disease

743

Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease

795

Transcriptomic profiling in DYT1 dystonia: unravelling pathogenic pathways.

837

Exploring the effects of torsinA dysfunction in an iPSC-derived neuronal model of TOR1A dystonia

865

AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington's disease minipigs up to 5 years

866

Effects of a small molecule angiotensin IV analog on Huntington's disease animal model

941

Stiff-Person Syndrome: Diagnosis and Experimental Models

957

Anti-tremor efficacy of Nabiximols (JZP378) in a rat Model of essential tremor

958

Frequency coding mechanism of tremor in the cerebellar circuitry

1031

Mosaic divergent repeat interruptions in X-linked dystonia-parkinsonism: stability over generations and time

1049

Impacts of mutations in Parkinson's disease-related genes on telomere maintenance

1050

Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson's disease patients.

1051

The role of RNA-carrying exosomes in synaptic physiology and in synucleinopathies

1053

Genome Wide Association Studies using TRACTOR reveals new associated loci with Parkinson Disease in a Latino Cohort

1054

Uncovering the mechanisms of genotype by environment interaction in an idiopathic Parkinson's disease model in Drosophila

1055

The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening

1056

Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson's disease: comparison with plasma miRNA

1057

Genome-wide association identifies novel etiological insights associated with Parkinson's Disease in African and African admixed populations

1058

Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson's disease

1134

Conventional anti-epileptic drugs used in North Sea Progressive Myoclonus Epilepsy revisited in a Drosophila model

1193

In vitro α -synuclein aggregation and propagation model

1194

Alterations in Cortico-basal ganglia Directed Connectivity in Parkinsonism and during Therapeutic STN DBS

- 1195
Representation of movement repertoire in subthalamic neural circuits using a markerless 3D behavioral tracking system.
- 1196
The changes in alpha-synuclein level and oscillatory activity of substantia nigra by nigral electrical stimulation
- 1246
Pathological neuronal Oscillations in an animal model of Rapid-Onset Dystonia-Parkinsonism
- 1249
Evoking Parkinsonism in Mice by a Pharmacological Approach Combined with Targeted Viral-based Manipulations of Neuronal Ensembles
- 1250
Dopaminergic Neuronal attributes in aging Substantia Nigra and Ventral Tegmental Area of mice strains distinctly sensitive to MPTP
- 1251
A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
- 1252
Decreased α -synuclein membrane-binding in the enteric nervous system as a marker of early pathology in Parkinson's disease
- 1253
The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson's disease
- 1255
Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming
- 1256
IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with synucleinopathy
- 1329
Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
- 1330
Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
- 1333
Effect of the 5-HT_{2A/2C} inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
- 1334
Quantitative investigation of the pathway between dopamine receptors and Ca²⁺ channels in layer II stellate cells towards Parkinson's disease
- 1336
Polyaromatic hydrocarbons in Ambient Particulate Matter (PM 2.5) mediate neurodegeneration through the olfactory-brain axis in C57BL/6 mice
- 1337
The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
- 1344
The induction of mitochondrial damage by alpha synuclein In Parkinson's disease.
- 1346
Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson's disorder
- 1347
Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains
- 1348
Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model

- 1350
Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson's disease
- 1351
Therapeutic effects of citral nanoliposome on Parkinson's treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways
- 1352
Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline
- 1353
Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson's disease in a marmoset monkey model
- 1354
The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
- 1357
modulation of sodium potassium ATPase activity by norepinephrine and serotonin to find an effective cure of parkinson's disease by introducing the novel concept of insilico drug repurposing
- 1358
Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.
- 1359
Glunomab: a novel therapeutics for the treatment of Parkinson's Disease
- 1360
LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte-derived macrophages and SH-SY5Y
- 1361
Investigation of superficial brain stimulation (SBS) in Parkinsonian rats as a non-invasive alternative treatment for patients with movement disorders
- 1362
Development of therapeutic substances for the disassembly of α -synuclein aggregates as disease-modifying treatment of synucleinopathies
- 1363
Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson's Disease Based on Network Pharmacology and Molecular Docking
- 1452
Metabolic modulation of mitochondrial DNA release in cellular models of Parkin-associated Parkinson's disease
- 1453
miRNAs from blood serum as an early diagnostic biomarker for Parkinson's disease: A study in an animal model
- 1454
Sub-cellular alterations in MPTP-induced in-vivo and in-vitro systems and Non-MPTP human Parkinsonian skin biopsies: Verifying the sequelae of differential toxicity
- 1455
LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia
- 1456
Inhibition of LRRK2 kinase activity promotes glucocerebrosidase transport to the lysosomes in primary monocyte-derived macrophages from patients with GBA-associated Parkinson's disease
- 1457
SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models

- 1458
Impaired CaMKII/ERK activation in mouse mutant LRRK2 R1441G fibroblasts was associated with reduced mitochondrial calcium store and efflux in response to depolarization stress
- 1459
Glycated alpha-synuclein and its emerging role in early onset of Parkinson's disease
- 1460
SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson's disease progression
- 1461
Small Molecule Inhibitors for Precise Inhibition of α -Synuclein Oligomer Generation in Parkinson's Disease (PD)
- 1462
Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield
- 1463
Exploring mitochondrial mechanisms defining Parkinson's disease penetrance in LRRK2 G2019S neuronal cultures
- 1464
Characterization of the pathogenic α -Synuclein variant p.V15A in Parkinson's disease
- 1466
Parkin Coregulates Glutathione Metabolism in Adult Brain to Contribute to Redox Homeostasis
- 1467
Proteomic profiles analysis of plasma exosomes and WBC reveals new insights of PD patients classified into H&Y clinical stage
- 1468
A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson's disease
- 1471
Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson's disease
- 1474
Membrane-associated properties and ER stress alterations in LRRK2 I1371V patient iPSC derived neurons increase susceptibility to oxidative stress.
- 1475
Targeting autophagy to identify novel modulators of Parkinson's disease using midbrain organoids
- 1476
The Role of Adaptive Immunity caused by α -synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson's Disease Pathogenesis
- 1477
Selenium mitigates ferroptosis-mediated dopaminergic cell death by regulating the Nrf2/GPX4 pathway: Implication for Parkinson's disease
- 1478
Impaired lysophagy function exacerbates propagation of α -synuclein aggregation
- 1479
Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced- Parkinson's disease model
- 1480
Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia
- 1481
Hypoxia-induced astrocyte activation and its protective effect on Parkinson's disease
- 1482
LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α -synuclein through NF- κ B pathway

- 1483
Lysosomal-driven reduction of α -synuclein aggregates in a neuron-like model of Parkinson's disease
- 1484
Identification of reproducible metabolites for Parkinson's Disease diagnosis using clinical data and computational modelling
- 1485
Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's Disease mouse model
- 1486
Selegiline drives autophagic secretion of α -synuclein
- 1487
Distinct temporal and spatial alteration of immunoproteasome in Parkinson's Disease pathogenesis
- 1488
Impaired Mitophagy and Mitochondrial-energetics in Parkinson's disease: A Novel Therapeutic Strategy of Re-tasking Felodipine
- 1489
Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?
- 1490
Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.
- 1491
Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson's Disease
- 1493
RNA editing contributes to the inflammatory astrocytic response in Parkinson's disease.
- 1494
TREM2 maintain microglial proliferation and α -syn accumulation in PD models via the PI3K-Akt pathway
- 1495
The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson's Disease
- 1746
Characterizing the neural response to electrical brain stimulation with spatiotemporal precision in mice.
- 1813
Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats
- 1814
Role of nanoparticles of berberine on oxidative stress in nigrostriatal tissue and neurobehavioral characteristics in rotenone induced animal model of Parkinson's disease
- 1939
Age-associated changes in the striatal proteins in aging Asian-Indians
- 1940
The effect of anti- Parkinson's disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson's disease